Table 2.
Outcome Measures of Effectiveness in the Efficacy Evaluable Population - by treatment
| Switch (N=89) | Stay (N=98) | Difference (95% CI) | P value* | |
|---|---|---|---|---|
| Primary Outcome | ||||
|
| ||||
| Change in Framingham Risk Score | −0.018 ± 0.0030 | −0.010 ± 0.0026 | 0.008 (0.000,0.016) | 0.0429# |
|
| ||||
| Other Secondary Outcomes | ||||
| Metabolic Outcomes | ||||
|
| ||||
| Change in weight (kg) | −3.6 ± 0.48 | −0.7 ± 0.44 | 29 (1.6,4.2) | <.0001# |
|
| ||||
| Change in LDL Cholesterol (mg/dL) | −15.4 ± 27.6 | −12.5 ± 2.54 | 2.9 (−3.9,9.6) | 0.4003 |
|
| ||||
| Change in HDL Cholesterol (mg/dL) | 0.6 ± 0.76 | −0.1 ± 0.68 | −0.7 (−2.7,1.3) | 0.4693# |
|
| ||||
| Change in Triglycerides (mg/dL) | −25.7 ± 8.10 | 7.0 ± 7.20 | 32.7 (12.1,53.4) | 0.0020 |
|
| ||||
| Change in TG/HDL ratio | −0.8 ± 0.25 | 0.2 ± 0.22 | 1.0 (0.3,1.6) | 0.0029# |
|
| ||||
| Change in fasting glucose (mg/dL) | 0.5 ± 1.43 | 4.0 ± 1.25 | 3.5 (−0.2,7.1) | 0.0607 |
|
| ||||
| Change in waist circumference (inches) | −1.4 ± 0.25 | −0.5 ± 0.22 | 0.9 (0.2,1.5) | 0.0075# |
|
| ||||
| Change in systolic bood pressure (mmHg) | −3.4 ± 1.39 | −1.0 ± 1.23 | 23 (−1.0,5.7) | 0.1753 |
|
| ||||
| Change in diastolic blood pressure (mmHg) | −3.2 ± 1.18 | −1.8 ± 1.07 | 1.4 (−1.2,4.0) | 0.2937 |